Tamiflu

oseltamivir phosphate

Tamiflu

Pharmacologic class: Viral neuro-aminidase inhibitor

Therapeutic class: Antiviral

Pregnancy risk category C

Action

Inhibits influenza virus neuraminidase, altering viral particle aggregation and decreasing viral release from infected cells

Availability

Capsules: 30 mg, 45 mg, 75 mg

Powder for oral suspension: 12 mg/ml

Indications and dosages

➣ To prevent influenza type A

Adults and children older than age 13: 75 mg P.O. daily for 10 days, starting within 2 days of exposure; 75 mg P.O. daily during community outbreak of influenza for up to 6 weeks

Children ages 1 and older weighing more than 40 kg (88 lb): 75 mg P.O. daily for 10 days, starting within 2 days of exposure; continue dosing during community outbreak of influenza for up to 6 weeks

Children ages 1 and older weighing more than 23 kg up to 40 kg (more than 51 lb up to 88 lb): 60 mg P.O. daily for 10 days, starting within 2 days of exposure; continue dosing during community outbreak of influenza for up to 6 weeks

Children ages 1 and older weighing more than 15 kg up to 23 kg (33 lb up to 51 lb): 45 mg P.O. daily for 10 days, starting within 2 days of exposure; continue dosing during community outbreak of influenza for up to 6 weeks

Children ages 1 and older weighing 15 kg (33 lb) or less: 30 mg P.O. daily for 10 days, starting within 2 days of exposure; continue dosing during community outbreak of influenza for up to 6 weeks

➣ Treatment of influenza type A

Adults and children older than age 13: 75 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset

Children ages 1 and older who weigh more than 40 kg (88 lb): 75 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset

Children ages 1 and older who weigh more than 23 kg and up to 40 kg (51 to 88 lb): 60 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset

Children ages 1 year and older who weigh more than 15 kg and up to 23 kg (33 to 51 lb): 45 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset

Children ages 1 and older who weigh less than 15 kg (33 lb): 30 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset

Dosage adjustment

• Renal impairment

Contraindications

• Hypersensitivity to drug or its components

Precautions

Use cautiously in:

• chronic cardiac or renal disease, respiratory disorders

• elderly patients

• pregnant or breastfeeding patients

• children younger than age 1 (safety and efficacy not established).

Administration

• For flu treatment, give first dose at onset of symptoms. For flu prevention, give within 2 days of exposure.

Adverse reactions

CNS: headache, dizziness, fatigue, insomnia, unusual behavior, confusion

GI: nausea, vomiting, diarrhea

Respiratory: cough, bronchitis

Skin: epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome

Other: hypersensitivity reactions (including anaphylaxis)

Interactions

None significant

Patient monitoring

See Monitor patient closely for allergic reaction or severe rash; discontinue drug immediately if these occur.

• Closely monitor patient for unusual behavior or confusion.

• Monitor respiratory status. Watch for signs and symptoms of secondary infection.

Patient teaching

• Instruct patient to take as soon as flu symptoms occur and to complete entire course of therapy.

• Advise patient to take with food or milk to minimize GI irritation.

• Tell patient to prepare oral solution by adding water to powder and shaking well.

See Instruct patient or caregiver to discontinue drug and seek immediate medical attention if rash or swelling of lips, face, or throat occurs

• Instruct patient or caregiver to report change in behavior.

• Caution patient not to share drug with others, even if they have similar symptoms.

• Instruct patient to consult prescriber before taking other drugs.

• As appropriate, review all other significant adverse reactions.

Tamiflu

(tăm′ə-flo͞o′) A trademark for the phosphate form of the drug oseltamivir.

oseltamivir

An antiviral ingested as a prodrug, which is used to manage influenza A or B. A Cochrane review published in 2009 found no clear benefit for oseltamivir if taken after the first 24 hours.

Adverse events
Nausea, vomiting, diarrhoea, abdominal pain, and headache.

Tamiflu®

Oseltamivir Infectious disease An oral neuraminidase inhibitor used for influenza A and B

Tamiflu

A brand name for OSELTAMIVIR.

单词	tamiflu
释义	Tamiflu Tam·i·flu T5033750 (tăm′ə-flo͞o′) A trademark for the phosphate form of the drug oseltamivir. Tamiflu (ˈtæmɪˌfluː) n (Pathology) trademark an oral antiviral drug that attacks the influenza virus and prevents it spreading inside the body Tamiflu oseltamivir phosphate Tamiflu *Pharmacologic class:* Viral neuro-aminidase inhibitor *Therapeutic class:* Antiviral *Pregnancy risk category C* Action Inhibits influenza virus neuraminidase, altering viral particle aggregation and decreasing viral release from infected cells Availability Capsules: 30 mg, 45 mg, 75 mg Powder for oral suspension: 12 mg/ml Indications and dosages ➣ To prevent influenza type A Adults and children older than age 13: 75 mg P.O. daily for 10 days, starting within 2 days of exposure; 75 mg P.O. daily during community outbreak of influenza for up to 6 weeks Children ages 1 and older weighing more than 40 kg (88 lb): 75 mg P.O. daily for 10 days, starting within 2 days of exposure; continue dosing during community outbreak of influenza for up to 6 weeks Children ages 1 and older weighing more than 23 kg up to 40 kg (more than 51 lb up to 88 lb): 60 mg P.O. daily for 10 days, starting within 2 days of exposure; continue dosing during community outbreak of influenza for up to 6 weeks Children ages 1 and older weighing more than 15 kg up to 23 kg (33 lb up to 51 lb): 45 mg P.O. daily for 10 days, starting within 2 days of exposure; continue dosing during community outbreak of influenza for up to 6 weeks Children ages 1 and older weighing 15 kg (33 lb) or less: 30 mg P.O. daily for 10 days, starting within 2 days of exposure; continue dosing during community outbreak of influenza for up to 6 weeks ➣ Treatment of influenza type A Adults and children older than age 13: 75 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset Children ages 1 and older who weigh more than 40 kg (88 lb): 75 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset Children ages 1 and older who weigh more than 23 kg and up to 40 kg (51 to 88 lb): 60 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset Children ages 1 year and older who weigh more than 15 kg and up to 23 kg (33 to 51 lb): 45 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset Children ages 1 and older who weigh less than 15 kg (33 lb): 30 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset Dosage adjustment • Renal impairment Contraindications • Hypersensitivity to drug or its components Precautions Use cautiously in: • chronic cardiac or renal disease, respiratory disorders • elderly patients • pregnant or breastfeeding patients • children younger than age 1 (safety and efficacy not established). Administration • For flu treatment, give first dose at onset of symptoms. For flu prevention, give within 2 days of exposure. Adverse reactions CNS: headache, dizziness, fatigue, insomnia, unusual behavior, confusion GI: nausea, vomiting, diarrhea Respiratory: cough, bronchitis Skin: epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome Other: hypersensitivity reactions (including anaphylaxis) Interactions None significant Patient monitoring See Monitor patient closely for allergic reaction or severe rash; discontinue drug immediately if these occur. • Closely monitor patient for unusual behavior or confusion. • Monitor respiratory status. Watch for signs and symptoms of secondary infection. Patient teaching • Instruct patient to take as soon as flu symptoms occur and to complete entire course of therapy. • Advise patient to take with food or milk to minimize GI irritation. • Tell patient to prepare oral solution by adding water to powder and shaking well. See Instruct patient or caregiver to discontinue drug and seek immediate medical attention if rash or swelling of lips, face, or throat occurs • Instruct patient or caregiver to report change in behavior. • Caution patient not to share drug with others, even if they have similar symptoms. • Instruct patient to consult prescriber before taking other drugs. • As appropriate, review all other significant adverse reactions. Tamiflu (tăm′ə-flo͞o′) A trademark for the phosphate form of the drug oseltamivir. oseltamivir An antiviral ingested as a prodrug, which is used to manage influenza A or B. A Cochrane review published in 2009 found no clear benefit for oseltamivir if taken after the first 24 hours. Adverse events Nausea, vomiting, diarrhoea, abdominal pain, and headache. Tamiflu® Oseltamivir Infectious disease An oral neuraminidase inhibitor used for influenza A and B Tamiflu A brand name for OSELTAMIVIR.
随便看	sequential hermaphrodites sequential hermaphroditism sequential importance resampling joint probabilistic data association filter sequential importance sampling sequential injection sequential injection analysis sequential iterative interference cancellation sequentiality sequential landform sequential likelihood ratio test sequential linear programming sequential linear test sequential lobing sequential logic sequential logic element sequential logic equivalence checking sequentially sequentially compact sequentially compact space sequentially-compact space sequentially controlled automatic transmitter start sequential machine sequential manual gearbox sequential manual transmission sequential math course

Tamiflu

Tam·i·flu

Tamiflu

Tamiflu

oseltamivir phosphate

Action

Availability

Indications and dosages

Dosage adjustment

Contraindications

Precautions

Administration

Adverse reactions

Interactions

Patient monitoring

Patient teaching

Tamiflu

oseltamivir

Tamiflu®

Tamiflu